SNY: SANOFI-AVENTIS - Commentary - Zacks Investment Research

ESTIMATES
Detailed Estimates

55.05

                        Sanofi: (NYSE: SNY)
                    
                                    $54.56
                                
                                    -0.49 (-0.89%)
                                
                                    Volume 1,182,206
                                
                                    May 23 04:03 PM ET
                                
Zacks Rank: 4-Sell  

#4
 
This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below. 

                                                                    Zacks Rank
                                                                    Definition
                                                                    Annualized Return
                                                                
                                                                    #1
                                                                    Strong Buy
                                                                    26.6%
                                                                
                                                                    #2
                                                                    Buy
                                                                    18.71%
                                                                
                                                                    #3
                                                                    Hold
                                                                    10.12%
                                                                
                                                                    #4
                                                                    Sell
                                                                    4.32%
                                                                
                                                                    #5
                                                                    Strong Sell
                                                                    2.16%
                                                                
                                                                    S&P
                                                                    500
                                                                    9.93%
                                                                
                                                        Zacks Rank Education - Learn more about the Zacks Rank
Zacks Rank Home - All Zacks Rank resources in one place
Zacks Premium - The only way to get access to the Zacks Rank
Zacks Commentary

                            Get Zacks Commentary for:
                            
            Zacks Commentary For SNY
        
May 23, 2013 Zacks Blog: Encouraging News for Peregrine Pharma
May 22, 2013 Zacks Blog: Sanofi/REGN's Dupilumab Data Published
May 16, 2013 Zacks Blog: The Zacks Analyst Blog Highlights: Genomic Health, Sanofi, Regeneron Pharmaceuticals, Amgen and Isis Pharmaceuticals
May 15, 2013 Zacks Blog: Sanofi/REGN Commence Enrollment
May 15, 2013 Zacks Blog: FDA Accepts Merck BLA
May 09, 2013 Zacks Blog: Narrower than Expected Loss at Infinity
May 08, 2013 Zacks Blog: Osiris Loss In-Line with Expectations
May 08, 2013 Zacks Blog: Isis Reports In-Line Loss
May 08, 2013 Zacks Blog: MYGN Earnings Easily Beat, Guidance Up
May 07, 2013 Zacks Blog: Merck's Liptruzet Approved in the US
May 07, 2013 Zacks Blog: The Zacks Analyst Blog Highlights: Bristol-Myers Squibb, Sanofi, AbbVie, Celgene and Telus
May 06, 2013 Zacks Blog: Good News for Bristol-Myers

<a href="#"><img id="dart_image_1" src="http://b7d61a7c6b8c307bf531-a92a66b9587e2a0aa805bd4e70b98407.r95.cf2.rackcdn.com/images/zacks/logos/zacks_logo_230x76.png" width="728" height="90" border="0" alt="" /></a>                

                            Quick Links
                        
Services

                                            Premium Services
Zacks Rank
Personal Finance
Commentary
Education

                                        
My Account

                                            Manage Account
Update Profile
Subscriptions
Preferences
Login/Password Help
Upgrade to Premium

                                        
Resources

                                            Help
FAQs
Disclosure
Privacy Policy
Performance
Site Map

                                        
Client Support

                                            Contact Us
Share Feedback
About Zacks
Careers
Advertise
Media

                                        
Follow Us
Facebook
Twitter
Linkedin
RSS
You Tube
Zacks Research is Reported On:

                                            
                                            
                                            
                                            
                                            
                                            
                                            
                                        
Zacks Investment Research
is an A+ Rated BBB
Accredited Business.
Copyright 2013 Zacks Investment Research
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1986 it has nearly tripled the S&P 500 with an average gain of +26% per year. These returns cover a period from 1986-2011 and were examined and attested by Baker Tilly, an independent accounting firm.
Visit performance for information about the performance numbers displayed above.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.